

**MOVEMENT DISORDERS****Sunday, March 29, 2020****07:30-08:30 E-Poster Presentations (Exhibition Area)****08:30-10:10 NEUROSURGERY FOR MOVEMENT DISORDERS**Chairs: **Heather Wilson**, UK**08:30-09:20 Is there a role for stereotactic ablation in movement disorders in the DBS era?**

*Capsule: DBS was introduced as an alternative to ablative therapy. The reversibility of the procedure and the ability to adjust the implanted stimulator was appealing. But over time the invasiveness, adverse events profile and the high cost of the procedure became apparent. The introduction of minimally invasive ablative treatments such as MRI guided focused ultrasound have raised the question of whether it is time to reintroduce ablative procedures as an alternative to DBS.*

08:30-08:40 Host: **Ilana Schlesinger**, Israel08:40-08:55 Yes: **John Duda**, USA08:55-09:10 No: **Abdelhamid Benazzouz**, France

09:10-09:20 Discussion and rebuttals

**09:20-10:10 DBS in tardive dyskinesia?**

*Capsule: Treatment options for tardive dyskinesias include pharmacological interventions, but the effects are limited and new pharmacological forms of tetrabenazine (i.e. valbenazine) are expensive and may be associated with depression or parkinsonism. May DBS offer a good treatment option for refractory and severe cases?*

09:20-09:30 Host: **Laxman Bahroo**, USA09:30-09:45 Yes: **Jaroslav Slawek**, Poland09:45-10:00 No: **Sharon Hassin-Baer**, Israel

10:00-10:10 Discussion and rebuttals

**10:10-10:25 Coffee Break****10:25-12:05 SECTION TITLE**Chairs: **Edoardo de Natale**, UK |**10:25-11:15 Is there a role for neurosurgery in refractory Gilles de la Tourette syndrome (GdIT)?**

*Capsule: Neurosurgical advances in the treatment of movement disorders and psychiatric conditions continue to awe and change the therapeutic being one of those conditions, has benefited from such advances. However, many questions remain about the safety, indications and long-term outcomes in GdIT patients who have recalcitrant motor and psychiatric symptoms undergoing Neurosurgical procedures. Is there a role for neurosurgery in refractory GdIT?*

10:25-10:35 Host: **Nestor Galvez**, USA10:35-10:50 Yes: **Patricia Limousin**, UK

10:50-11:05 No:

11:05-11:15 Discussion and rebuttals

**11:15-12:05 PET Imaging is an expensive tool with poor external validity and not relevant for future biomarker projects.**11:15-11:25 Host: **John Duda**, USA11:25-11:40 Yes: **Jesse Cedarbaum**, USA

11:40-11:55 No:

11:55-12:05 Discussion and rebuttals